Who Paid My Doc
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of Dcc-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Research payments
$14,118,341
Through program year 2025, $14,118,341 in research payments was reported against A Master Protocol for the Multi-Cohort, Phase 1/2 Study of Dcc-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies, across 852 payments, paid by Deciphera Pharmaceuticals Inc..
- Paid by
- Deciphera Pharmaceuticals Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $8,653,603 | 647 |
| 2024 | Research | $5,374,261 | 196 |
| 2023 | Research | $90,477 | 9 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ping Chi New York, NY Named on 166 payments
- Margaret Von Mehren Philadelphia, PA Named on 158 payments
- Sreenivasa Chandana Grand Rapids, MI Named on 87 payments
- Syma Iqbal Los Angeles, CA Named on 80 payments
- Jonathan Trent Miami, FL Named on 69 payments
- Arun Singh Santa Monica, CA Named on 66 payments
- Dale Shepard Cleveland, OH Named on 57 payments
- Michael Heinrich Portland, OR Named on 53 payments
- Janice Mehnert New York, NY Named on 30 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.